The organoids are incredibly finicky until you figure out a culture system they like. Then it is actually very easy to maintain them. This allows us defensibility as it's hard for others to figure out but easier for us now that we have.
We've used the organoid to test 12 immunomodulators and confirmed they matched human clinical data. We also vaccinated the organoids against 8 infectious diseases and they produced a full immune response with class switching, germinal center formation, somatic hypermutation, etc. We're also in the process of using more historical controls to show that immune reactions that were missed in mice and other animals are captured in our system (e.g. there are highly inflammatory drugs that were safe in mice but deadly in people once they got to clinical trials).
By biobanking on diverse patient backgrounds, diseases are emulated in these organoids naturally. Immune disease is typically a function of dysfunctional cells that exist in a patient. By capturing an immune niche that has those cells, we have the disease-causing cells. We can confirm they emulate a disease by demonstrating a phenotype on a tissue of interest (e.g. we can make an MS immune organoid from a patient with MS and then show that the immune cells from the organoid demyelinate neurons). This should be the same for any immune disease as we continue to generate proof of concept.